Strs Ohio raised its position in shares of Repligen Corp. (NASDAQ:RGEN) by 9.6% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 35,400 shares of the company’s stock after buying an additional 3,100 shares during the period. Strs Ohio’s holdings in Repligen Corp. were worth $968,000 at the end of the most recent quarter.
Other large investors have also bought and sold shares of the company. Acrospire Investment Management LLC purchased a new stake in Repligen Corp. during the first quarter valued at about $106,000. BNP Paribas Arbitrage SA boosted its stake in Repligen Corp. by 122.3% in the second quarter. BNP Paribas Arbitrage SA now owns 10,542 shares of the company’s stock valued at $288,000 after buying an additional 5,800 shares during the last quarter. Virginia Retirement System purchased a new stake in Repligen Corp. during the first quarter valued at about $381,000. Louisiana State Employees Retirement System boosted its stake in Repligen Corp. by 2.1% in the second quarter. Louisiana State Employees Retirement System now owns 14,900 shares of the company’s stock valued at $408,000 after buying an additional 300 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its stake in Repligen Corp. by 16.4% in the second quarter. Capstone Asset Management Co. now owns 15,830 shares of the company’s stock valued at $433,000 after buying an additional 2,230 shares during the last quarter. Hedge funds and other institutional investors own 89.38% of the company’s stock.
Repligen Corp. (NASDAQ:RGEN) traded down 1.25% on Friday, reaching $29.32. 170,619 shares of the company’s stock were exchanged. Repligen Corp. has a 12-month low of $20.07 and a 12-month high of $36.00. The firm has a 50 day moving average of $31.51 and a 200-day moving average of $28.01. The company has a market cap of $990.61 million, a P/E ratio of 117.28 and a beta of 1.36.
Repligen Corp. (NASDAQ:RGEN) last announced its earnings results on Thursday, August 4th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.03. Repligen Corp. had a net margin of 8.69% and a return on equity of 10.74%. The business earned $29.20 million during the quarter, compared to analysts’ expectations of $24.75 million. During the same period in the prior year, the company earned $0.11 earnings per share. The business’s revenue was up 35.8% compared to the same quarter last year. Equities analysts expect that Repligen Corp. will post $0.44 EPS for the current fiscal year.
Separately, Zacks Investment Research raised shares of Repligen Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, August 11th.
In related news, Director Thomas F. Ryan, Jr. sold 2,700 shares of the stock in a transaction dated Wednesday, September 14th. The shares were sold at an average price of $32.58, for a total transaction of $87,966.00. Following the completion of the transaction, the director now directly owns 9,394 shares of the company’s stock, valued at $306,056.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.30% of the stock is currently owned by insiders.
About Repligen Corp.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corp. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.